Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema
Retinal Diseases Content Hub
Starting diabetic macular edema treatment with bevacizumab and switching to aflibercept if needed offers nearly identical vision outcomes to aflibercept monotherapy, but at a far lower cost. A cost-effectiveness analysis from the DRCR Retina Network found that aflibercept’s slight advantage in quality-adjusted life years does not justify its high price, which exceeds $800,000 per QALY gained.
